Table 1.
PET parameters of patients with thymic epithelial tumors according the WHO classification and Masaoka staging system
| No. of patients | SUVmax | MTV | TLG | |||
| Mean ± SD (range) | Mean ± SD (range) | Mean ± SD (range) | ||||
| WHO classification | ||||||
| Low-risk thymoma (A-B1) | 17 | 2.9 ± 0.8 (1.2–4.1) | 7.0 ± 11.9 (0–46.8) | 20.3 ± 35.9 (0–142.3) | ||
| Type A | 1 | 4.6 | 5.0 | 16.5 | ||
| Type AB | 9 | 3.0 ± 0.6 (2.4–4.1) | 10.5 ± 15.7 (0–46.8) | 30.7 ± 47.5 (0–142.3) | ||
| Type B1 | 7 | 2.7 ± 0.7 (1.2–3.3) | 2.8 ± 3.4 (0–8.6) | 7.6 ± 9.2 (0–24.3) | ||
| High-risk thymoma (B2-B3) | 8 | 3.8 ± 1.9 (1.8–7.5) | 28.7 ± 37.7 (0–91.0) | 110.8 ± 158.8 (0–382.6) | ||
| Type B2 | 4 | 4.6 ± 2.5 (2.0–7.5) | 52.0 ± 43.9 (0–91.0) | 205.6 ± 186.1 (0–382.6) | ||
| Type B3 | 4 | 3.0 ± 0.9 (1.8–3.8) | 5.4 ± 5.2 (0–10.8) | 16.0 ± 15.9 (0–33.0) | ||
| Carcinoma | 7 | 5.0 ± 1.4 (3.7–8.0) | 73.0 ± 145.5 (2.7–396.5) | 229.5 ± 434.8 (9.5–1181.6) | ||
| Masaoka staging system | ||||||
| Early stage (I-II) | 24 | 3.2 ± 1.1 (1.2–5.6) | 9.7 ± 20.1 (0–91.0) | 31.6 ± 73.0 (0–342.2) | ||
| Stage I | 13 | 2.6 ± 0.7 (1.2–3.6) | 4.3 ± 7.1 (0–25.0) | 12.1 ± 20.2 (0–71.0) | ||
| Stage II | 11 | 3.8 ± 1.1 (2.5–5.6) | 15.9 ± 28.1 (0.1–91.0) | 54.6 ± 103.4 (0.3–342.2) | ||
| Advanced stage (III-IV) | 8 | 4.8 ± 1.9 (2.7–8.0) | 78.6 ± 132.6 (2.7–396.5) | 260.6 ± 399.6 (9.5–1181.6) | ||
| Stage III | 8 | 4.8 ± 1.9 (2.7–8.0) | 78.6 ± 132.6 (2.7–396.5) | 260.6 ± 399.6 (9.5–1181.6) | ||
All values are expressed as the mean ± standard deviation. MTV, metabolic tumor volume; PET, positron emission tomography; SD, standard deviation; SUVmax, maximum standardized uptake value; TLG, total lesion glycolytic activity; VOI, volume of interest; WHO, World Health Organization.